Iberpapel reported operating profit of €13.77 million in the first nine months of the year, compared to €6.2 million in the same period of 2022. Having successfully defended its sales prices and margins, the company managed to eke out growth of 122% in a complicated environment marked by slowing demand in Europe and growing imports (especially from Asia), driving a drop in sales volumes and lower capacity utilisation.
Iberpapel reports a net profit of €34.96 million in the first nine months of 2023 Oct 27, 2023 Operating profit before the gain from the sale of forest land in.
21st Austria weekly - Valneva Andritz 16/05/2022 [pic1]Valneva: an Austrian/French specialty vaccine company announced that it has received a notice from the European Commission EC of intent to terminate advance purchase agreement APA for Valneva’s inactivated whole-virus COVID-19 candidate VLA2001. The APA provides EC with right if VLA2001 had not marketing authorization Medicines Agency